Polycystic ovary syndrome (PCOS) affects an estimated 8–13% of women of reproductive age, according to the World Health Organization — yet it remains chronically undertreated. As GLP-1 receptor agonists like semaglutide and tirzepatide have reshaped metabolic medicine, researchers and patients are increasingly asking the same question: can these drugs help with PCOS?
The short answer is: possibly, and the early evidence is promising. But neither semaglutide nor tirzepatide is FDA-approved for PCOS — meaning any prescription is off-label use. This guide explains what the research shows, how the two drugs compare for PCOS specifically, and how to find a telehealth provider if you want to explore this option.
What Is PCOS? (The Metabolic Version)
PCOS is a hormonal disorder characterized by elevated androgens (male hormones), irregular or absent ovulation, and in many cases, polycystic ovaries on ultrasound. For purposes of GLP-1 therapy, the most clinically relevant aspect is the metabolic dimension: up to 70–80% of women with PCOS have some degree of insulin resistance, even when they aren't overweight.
Insulin resistance drives a cycle: high insulin stimulates the ovaries to produce more androgens, which disrupts ovulation, which worsens hormonal imbalance. Addressing insulin resistance is therefore a central goal in PCOS management — and it's the primary mechanism by which GLP-1s have generated clinical interest.
How GLP-1 Medications Help PCOS
GLP-1 receptor agonists work through several pathways that are directly relevant to PCOS:
Improving insulin sensitivity. GLP-1s stimulate glucose-dependent insulin secretion and suppress glucagon, which lowers fasting insulin and reduces the ovarian androgen signal. Studies in PCOS populations have documented significant reductions in fasting insulin and HOMA-IR (a standard insulin resistance marker).
Reducing body weight. Weight loss of even 5–10% can meaningfully restore ovulatory function in women with PCOS who carry excess weight. GLP-1s produce sustained weight loss — typically 10–22% of body weight in trials — at a rate that has not been matched by lifestyle intervention alone.
Lowering androgen levels. Several studies report reductions in total and free testosterone following GLP-1 treatment in women with PCOS, likely as a downstream effect of reduced insulin. Lower androgens are associated with improvements in irregular cycles, acne, and unwanted hair growth (hirsutism).
Semaglutide for PCOS: What the Evidence Shows
Semaglutide (the active ingredient in Ozempic and Wegovy) is the better-studied option for PCOS. A 2023 randomized controlled trial published in Fertility and Sterility found that semaglutide produced significantly greater improvements in weight, insulin resistance, and androgen levels compared to placebo in women with PCOS over 24 weeks.
Key findings across the published semaglutide-PCOS literature:
- Weight reduction: 10–15% average body weight loss at doses consistent with the Wegovy titration schedule
- Testosterone: Meaningful reductions in free and total testosterone in multiple studies
- Menstrual regularity: Improved cycle regularity reported in several observational studies and small RCTs — though this varies significantly by individual
- HOMA-IR: Consistently reduced in metabolic PCOS phenotypes
Important: Semaglutide does not have an FDA indication for PCOS. When a telehealth provider prescribes it for this purpose, it is off-label use.
Tirzepatide for PCOS: Emerging Evidence
Tirzepatide (the active ingredient in Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist — it activates two metabolic pathways rather than one. This dual mechanism produced greater average weight loss than semaglutide in head-to-head analysis, with the SURMOUNT-1 trial reporting up to 22.5% body weight reduction at the highest dose.
PCOS-specific clinical data for tirzepatide is more limited — most published work is from general obesity trials or small case series. However, its metabolic profile suggests several potential advantages for PCOS:
- Greater insulin sensitization through GIP receptor activation, which may produce more pronounced HOMA-IR reductions than GLP-1 alone
- Larger weight loss at therapeutic doses, which translates to greater hormonal benefit in weight-dependent PCOS phenotypes
- GIP receptor signaling may have direct ovarian effects, though this is preliminary and not yet established in human PCOS trials
Tirzepatide's PCOS application is also off-label, and the evidence base is still developing. Clinical trials specifically enrolling PCOS populations are ongoing as of 2026.
Head-to-Head Comparison
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| FDA indication for PCOS | None (off-label) | None (off-label) |
| PCOS-specific clinical data | Moderate — multiple RCTs and observational studies | Limited — emerging case series and subgroup analyses |
| Average weight loss (trials) | ~10–15% body weight | Up to 22.5% body weight |
| Insulin resistance improvement | Well-documented | Strong — potentially greater than semaglutide |
| Androgen reduction evidence | Multiple published studies showing reduction | Early data; extrapolated from weight/insulin effects |
| Menstrual regularity data | Reported in several studies | Not yet studied in PCOS trials |
| Compounded telehealth cost | $99–$299/month | $125–$399/month |
| Insurance coverage | Varies (off-label rarely covered) | Varies (off-label rarely covered) |
| Telehealth availability | Widely available | Widely available |
What to Ask Your Doctor
Before starting either medication for PCOS, bring these five questions to your provider:
-
"Do my metabolic markers support trying a GLP-1?" Ask for fasting insulin, HOMA-IR, and free testosterone. These numbers tell your provider whether insulin resistance is a meaningful driver in your case — and give a baseline to measure progress against.
-
"Which medication would you recommend for me, and why?" Semaglutide has more PCOS-specific data; tirzepatide may offer greater weight and insulin benefit. Your provider should be able to explain their reasoning based on your labs and history.
-
"How will we know if it's working?" Establish clear outcome targets: specific HOMA-IR or testosterone reductions, cycle regularity milestones, or weight goals. Set a 3-month and 6-month checkpoint.
-
"What does the dose titration schedule look like?" Both medications require slow dose escalation to minimize gastrointestinal side effects. Ask what schedule your provider uses and what to do if you experience nausea or other symptoms.
-
"Are there any contraindications I should know about?" Both medications carry warnings regarding personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Review your full medication list for interactions.
Cost and Insurance Reality
Neither semaglutide nor tirzepatide is covered by insurance for PCOS — insurers require an on-label indication, and PCOS is not one. Most patients pursuing GLP-1s for PCOS pay out of pocket through telehealth providers offering compounded medications.
Typical Telehealth Costs (Compounded)
| Medication | Monthly Cost Range | Notes |
|---|---|---|
| Semaglutide | $99–$299/month | Widely available; multiple providers |
| Tirzepatide | $125–$399/month | Slightly higher cost; availability varies by state |
Brand-name Wegovy or Zepbound for PCOS off-label use is unlikely to receive prior authorization. If you have insurance, ask your provider whether a diabetes indication exists on your chart that might support coverage — but note that prescribers must document an accurate indication.
Where to Find a Telehealth Provider
Not every telehealth GLP-1 provider is equipped to treat PCOS. Look for providers who:
- Have experience prescribing off-label for metabolic conditions
- Can order and interpret PCOS-related labs (fasting insulin, androgens, LH/FSH)
- Offer ongoing monitoring — not just a prescription and a shipping label
- Are licensed in your state
Use the TeleHealthAlly provider comparison tool to filter by medication availability, state, and cost. You can also review our guide to GLP-1 telehealth providers for a detailed breakdown of what each platform includes.
If fertility is a goal alongside metabolic health, look for providers who can coordinate with a reproductive endocrinologist or OB/GYN, as GLP-1s should generally be discontinued before conception.
Frequently Asked Questions
Is semaglutide or tirzepatide better for PCOS?
Neither has an FDA indication for PCOS — both are used off-label. Semaglutide has more published data in PCOS populations, including multiple randomized trials showing improvements in weight, insulin resistance, and androgen levels. Tirzepatide's dual GIP/GLP-1 mechanism may offer additional metabolic benefit, particularly for insulin resistance, but PCOS-specific clinical data is still limited. The right choice depends on your metabolic markers and your provider's clinical judgment.
Can GLP-1 medications help PCOS symptoms?
Evidence suggests GLP-1 receptor agonists can improve several PCOS-related metabolic markers — including insulin resistance, fasting glucose, body weight, and often elevated androgen levels. These improvements may translate to more regular cycles, reduced acne, and improved hirsutism in some patients, though response varies significantly. GLP-1s are not FDA-approved for PCOS; any prescription represents off-label use and should involve informed consent.
Can I get semaglutide or tirzepatide for PCOS through telehealth?
Yes. Several telehealth platforms prescribe GLP-1 medications for metabolic conditions including PCOS. Availability depends on your state's prescribing regulations, your clinical history, and the provider's individual policies. Use the TeleHealthAlly comparison tool to find providers offering GLP-1 medications in your state. Expect to pay out of pocket — insurance rarely covers off-label use for PCOS.
What outcomes can I realistically expect?
Most published PCOS studies report improvements in insulin resistance and modest androgen reductions within 12–24 weeks. Weight loss follows standard GLP-1 curves — typically 5–10% by month 3, potentially 15–22% by month 12 at full dose. Menstrual regularity improvements are reported in several studies but are not universal. Managing expectations around fertility is especially important: while hormonal normalization can improve fertility prospects, GLP-1 medications are not a fertility treatment and should be discontinued before attempting pregnancy.